The Food and Drug Administration last week approved a new drug for facilitating tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

FDA said that approving cisatracurium besylate USP 20 mg/10mL injections via an abbreviated new drug application addresses a shortage for a medical product that is in increased demand. The agency noted the drug’s side effects include bradycardia, hypotension, flushing, bronchospasm and rash.

Related News Articles

The National Institutes of Health will use $70 million from the American Rescue Plan Act for a program to speed development of accurate and reliable over-the-…
The Food and Drug Administration Monday approved a new injection to assist in tracheal intubation and provide muscle relaxation during surgeries or…